Anixa Biosciences Announces Maximum Tolerated Dose Reached In Trial Of Preventative Breast Cancer Vaccine

Published on December 08, 2022 07:49 AM PST

Dec 8 (Reuters) - Anixa Biosciences Inc:

* ANIXA BIOSCIENCES ANNOUNCES MAXIMUM TOLERATED DOSE REACHED IN TRIAL OF PREVENTATIVE BREAST CANCER VACCINE

* ANIXA BIOSCIENCES INC - MAXIMUM TOLERATED DOSE (MTD) HAS BEEN REACHED IN PHASE 1A TRIAL OF ITS PREVENTATIVE BREAST CANCER VACCINE

* ANIXA BIOSCIENCES INC - LOOK FORWARD TO PRESENTING COMPLETE IMMUNOLOGICAL DATA FROM TRIAL AT A SCIENTIFIC CONFERENCE OR SIMILAR SETTING IN Q2 OF 2023 Source text for Eikon: Further company coverage:

Reuters

Reuters -
96361 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.